Pharma BD Deal Intelligence
Lead Mitobridge asset (bocidelpar/ASP0367) failed its pivotal Phase 2 in 2024; the mitochondrial-medicine platform Astellas bought it for has been quietly dismantled, with other programs divested or shelved.
Full analysis, sources & comparables →Astellas's takeout of Cambridge-based Mitobridge represents a bet on mitochondrial-targeted therapeutics in a high-unmet-need space; the deal's milestone-heavy…
FDA granted Fast Track designation to ASP0367 for primary mitochondrial myopathies, validating Astellas's clinical-development thesis for the Mitobridge…
The MOUNTAINSIDE Phase 2/3 program enrolling 139 PMM adults at 14 US sites, using 6-minute walk test as primary endpoint, signals Astellas's commitment to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Astellas completed acquisition of Cambridge, MA-based Mitobridge in January 2018 for $225M upfront plus up to $225M in development milestones (total $450M). Built off a 2013 collaboration option, the deal accelerates Astellas's R&D in diseases linked to mitochondrial dysfunction, anchored by lead PPAR-delta modulator ASP0367 for primary mitochondrial myopathies.
Lead Mitobridge asset (bocidelpar/ASP0367) failed its pivotal Phase 2 in 2024; the mitochondrial-medicine platform Astellas bought it for has been quietly dismantled, with other programs divested or shelved.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Mitobridge, Inc. (this deal) | 2018 | $450M | 22 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
← Browse all deals · How we score deals
More: 2018 deals · Astellas Pharma Inc. deals · Rare Disease deals